MedTrace Logo

Treatment of Sodium Retention in Liver Cirrhosis With Dexamethasone

NCT01311167 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2013-04-18

No results posted yet for this study

Summary

Accumulation of salt and water in patients with liver disease (so called liver cirrhosis) is possibly related to the increased effect of steroid hormones on salt reabsorption in the kidney. By reducing overall steroid production with the dexamethasone the accumulation of salt and water could be prevented.

Conditions

Interventions

DRUG

Dexamethasone

Daily administration of 2 mg of dexamethasone for 4 days

DRUG

Placebo

Daily administration of 2 mg of placebo for 4 days

Sponsors & Collaborators

  • University Hospital, Geneva

    collaborator OTHER

  • University of Lausanne Hospitals

    collaborator OTHER

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01311167 on ClinicalTrials.gov